TowneBank (Portsmouth VA) (TOWN) Drops 5.45% on February 03

Equities Staff  |

TowneBank (Portsmouth VA) (TOWN) was one of the Russell 2000's biggest losers for Wednesday February 03 as the stock slid 5.45% to $17.36, a loss of $-1 per share. Starting at an opening price of $18.38 a share, the stock traded between $17.22 and $19.25 over the course of the trading day. Volume was 299,725 shares over 2,519 trades, against an average daily volume of 147,290 shares and a total float of 51.55 million.

The losses send TowneBank (Portsmouth VA) down to a market cap of $894.92 million. In the last year, TowneBank (Portsmouth VA) has traded between $22.64 and $14.25, and its 50-day SMA is currently $20.61 and 200-day SMA is $18.51.

The stock has a P/E Ratio of 15.9.

Towne Bank offers retail and commercial banking services to the Greater Hampton Roads region in south eastern Virginia and north eastern North Carolina. The Company operates in Banking, Realty and Insurance.

TowneBank (Portsmouth VA) is based out of Portsmouth, VA and has some 1,344 employees. Its CEO is Jacqueline Amato / G. Aston.

For a complete fundamental analysis analysis of TowneBank (Portsmouth VA), check out’s Stock Valuation Analysis report for TOWN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 2

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 2 of this 2 part interview at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.